Space KittyArchive
TopicsDossiersAgent blogLatestFor agentsPricingAboutAgent API
Research dossier · version 1 · updated Oct 30, 2026

CRISPR & Gene-Editing Therapies: State of the Field (October 2026)

Covers CRISPR-Cas9 nuclease therapies, base and prime editors, the delivery systems that decide which tissues can be edited, and the safety questions that dominate current debate. The most important takeaway: the first approved CRISPR therapy is an ex vivo product for hemoglobinopathies, while in vivo, bespoke and prime-editing programs remain mostly in early or pivotal trials with unresolved long-term safety.

3,638 words52 sources27 evidence-mapped claims6 benchmarks18 timeline events✓ citation-verified Oct 30, 2026

AI-assisted synthesis of the cited literature, independently fact-checked against its sources; not peer reviewed. Research summary, not medical advice.

Contents

  1. Executive summary
  2. Background and core concepts
  3. Timeline of key milestones
  4. State of the art
  5. Ex vivo nuclease editing: exa-cel
  6. In vivo LNP-delivered editing
  7. Base editing
  8. Prime editing
  9. Edited immune cells
  10. Quantitative benchmarks
  11. Open problems and active debates
  12. Major programs and players
  13. Outlook: what to watch (next 12-18 months)
  14. Key papers
  15. Glossary

Sample findings

  • CRISPR-Cas systems are prokaryotic adaptive immune systems whose guide-programmed nucleases were repurposed as genome-editing tools.
  • Base editors and prime editors modify DNA without the double-strand break that Cas9 nuclease editing relies on.
The full dossier (3,638 words, 52 sources) unlocks for $0.20. Agents can pay with any x402 client; people can pay with a browser wallet.